Targeting the Nociceptin/Orphanin FQ Receptor for Scleroderma Therapy

Abstract

Scleroderma is a debilitating disease of the connective tissue that affects about 75,000100,000 individuals in the United States and accounts for an estimated $400 million in total annual medical costs. There is no treatment that stops or cures scleroderma: novel therapies are therefore urgently needed. The overall objective of this proposal is to demonstrate that small molecule compounds that target receptor-ligand pair NOP receptorNociceptin/Orphanin FQ can limit the damage and malfunctions that occur in the immune system and in blood vessels during scleroderma. We anticipate that our approach will demonstrate that a single drug can limit inflammation, heal blood vessel damage, and increase blood flow.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Dec 01, 2015
Accession Number
AD1005084

Entities

People

  • Brian Zabel

Organizations

  • Palo Alto Veterans Institute for Research

Tags

DTIC Thesaurus Topics

  • Blood
  • Blood Vessels
  • Cell Line
  • Cells
  • Chemistry
  • Connective Tissue
  • Diseases And Disorders
  • Endothelial Cells
  • Immune System
  • Medical Personnel
  • Molecules
  • Monocytes
  • Patent Applications
  • Professional Development
  • Small Molecules
  • United States
  • Wound Healing

Fields of Study

  • Medicine

Readers

  • Immunology and Pathology
  • Neurotrauma and Rehabilitation Medicine.